Recent

% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

  • wbill909 wbill909 Nov 9, 2012 3:41 PM Flag

    Here some more NCE support..

    Over past 48 hours I have referenced several FDA attorneys as well as the work of a biochemist that wrote the actual patent data found in Amarin's key composition of matter patent. I am very confident that AMRN will gain NCE status based on FDA characterizing the active moiety different than that of Lovaza. On its face, it appears a close call and fairly complex since Lovaza is made up of DHA and EPA. However, FDA has decided that that combination of those elements work as ethyl esthers. Once you understand the mechanism of action and what AMRN found with their compound that Lovaza did not, it actually becomes much more clear. Currently, the FDA does not have any approved Rx containing icosapent ethyl alone or in combination as active moiety. The key is icosapent ethyl and it is not found alone or in combination. Period.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
AMRN
1.920.00(0.00%)May 26 4:00 PMEDT